I think just proving ddRNAi works in humans will suffice even if...

First 3 Last

Share
Profile

Follow
SmokeyNYY

587 Posts.

19/09/14

10:50

Post #: 13999193
Share

Originally posted by J8 ↑

Adherence issues need to be addressed by the consulting doctors. In the past patients have not been advised with enough conviction about the importance of adherence. This is changing..... any combination is going to have issues and the more pills or the longer the regime has to be taken will take its toll.

New treatments are coming but they are mainly combinations and will suffer the same fate in the compliance stakes.

HOWEVER:
Gilead's new Ledipasvir/Sovaldi single pill (once per day) will be FDA approved in THREE WEEKS.
It is just an eight week course for most patients and compliance will not be so much of an issue. As high as 99% cure rate! Relapsers and non responders will still have to take Ribavirin and extend the course out to twelve weeks.

Australian authorities IMO have been stalling approvals and are waiting for this latest combination to be US approved before making their move. IMO, there will be little demand for anything other than the new single pill combo until people can visit Uncle Benny's one stop shop sometime in 2018.
Gilead are curing about 14,000 people per month (this is blockbusting record breaking stuff) at present.......and it is only just keeping up the reinfection rate.

This means that even by 2018 the market will be still be huge for Benitec.

Expand

I think just proving ddRNAi works in humans will suffice even if it is too late for TT-034 to be of any use to anyone. The important thing is we will soon have multiple drugs in the clinic with Tribetarna. That alone could be enormous. Plus Cal-1. I think we will be alright even if TT-034 never is commercialized.

BLT Price at posting: $1.05 Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

Bitcoin investors need to know the risks

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

There are more pages in this discussion • 11 more messages in this thread...

First 3 Last

Add BLT (ASX) to my watchlist

I think just proving ddRNAi works in humans will suffice even if...

Top Stories

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Immutep reports strong response rate from immunotherapies treating carcinomas

Bitcoin investors need to know the risks

Almonty locks in govt agreement for tungsten oxide plant in South Korea

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nimy to raise $1.21M to explore 'newsy' WA targets

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Featured News